Zacks Small Cap Predicts Aethlon Medical Q1 Earnings

Aethlon Medical, Inc. (NASDAQ:AEMD) – Equities researchers at Zacks Small Cap issued their Q1 2026 earnings per share estimates for shares of Aethlon Medical in a research note issued on Wednesday, July 2nd. Zacks Small Cap analyst M. Marin forecasts that the medical equipment provider will post earnings of ($0.68) per share for the quarter. The consensus estimate for Aethlon Medical’s current full-year earnings is ($0.73) per share. Zacks Small Cap also issued estimates for Aethlon Medical’s Q2 2026 earnings at ($0.68) EPS, Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($1.49) EPS and FY2026 earnings at ($3.53) EPS.

Several other equities research analysts have also recently commented on AEMD. Wall Street Zen initiated coverage on Aethlon Medical in a research note on Thursday, May 15th. They issued a “sell” rating for the company. HC Wainwright restated a “buy” rating and issued a $56.00 target price on shares of Aethlon Medical in a report on Monday, March 10th.

Aethlon Medical Stock Performance

Shares of NASDAQ AEMD opened at $1.27 on Thursday. The stock has a market cap of $3.29 million, a price-to-earnings ratio of -0.10 and a beta of 1.69. The business has a 50 day simple moving average of $2.53 and a 200 day simple moving average of $3.70. Aethlon Medical has a 52 week low of $1.10 and a 52 week high of $8.44.

Institutional Trading of Aethlon Medical

Institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC bought a new stake in shares of Aethlon Medical during the fourth quarter valued at approximately $25,000. Sassicaia Capital Advisers LLC bought a new stake in shares of Aethlon Medical during the fourth quarter valued at approximately $31,000. Virtu Financial LLC bought a new stake in shares of Aethlon Medical during the fourth quarter valued at approximately $81,000. Boothbay Fund Management LLC bought a new stake in shares of Aethlon Medical during the fourth quarter valued at approximately $186,000. Finally, Armistice Capital LLC bought a new stake in shares of Aethlon Medical during the first quarter valued at approximately $511,000. 1.99% of the stock is currently owned by institutional investors.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.